Postpartum Depression (PPD)

The short version

●Postpartum depression (PPD) in DSM-5-TR is major depressive disorder with the "with peripartum onset" specifier — onset during pregnancy or within four weeks of delivery. Many clinicians and researchers use a broader window of one year postpartum.
●Approximately 1 in 7-10 birthing parents experience PPD; the rate is higher in patients with prior depression history, sleep-deprived states, and limited social support.
●Edinburgh Postnatal Depression Scale (EPDS) is the standard screening tool, validated for use through one year postpartum. Score ≥10 prompts clinical assessment; ≥13 strongly suggests PPD.
●FDA-approved PPD-specific treatments: brexanolone (Zulresso, IV neurosteroid, 60-hour infusion, 2019 approval) and zuranolone (Zurzuvae, oral neurosteroid, 14-day course, 2023 approval). These are GABA-A receptor positive allosteric modulators with distinct mechanism from SSRIs.
●SSRIs (sertraline, paroxetine, citalopram) remain first-line for many patients because of accessibility and breastfeeding compatibility — all three are considered relatively safe in lactation per current evidence.
●Ketamine's evidence base in PPD specifically is preliminary. Single-dose perioperative ketamine has been studied for PPD prevention with mixed results; treatment of established PPD with ketamine is investigational.

Clinical definition

DSM-5-TR diagnoses PPD as major depressive disorder with the "with peripartum onset" specifier — episode begins during pregnancy or within four weeks following delivery. Many epidemiological and clinical sources use a broader window of up to 12 months postpartum, reflecting the actual onset pattern observed in practice. ICD-10 codes PPD under F53.0 (mild) or F53.1 (severe) when associated with the puerperium. The clinical picture includes typical major depressive symptoms (depressed mood, anhedonia, sleep disturbance, appetite change, fatigue, guilt, concentration problems, suicidal ideation) plus pregnancy/postpartum-specific features (intrusive thoughts about the baby, anxiety about caregiving competence, difficulty bonding, ego-dystonic thoughts of harm to baby that distinguish from postpartum psychosis). Screening: Edinburgh Postnatal Depression Scale (EPDS) is the standard 10-item self-report instrument, validated from late pregnancy through 12 months postpartum. EPDS score 10-12 prompts clinical assessment; ≥13 strongly suggests probable PPD. Differential diagnosis includes postpartum blues (transient, 2-week limit, no marked impairment), postpartum psychosis (psychotic symptoms, mood instability, requires urgent psychiatric care), and pre-existing depression with peripartum continuation.

How it differs from related conditions

vs. Postpartum (baby) blues

Transient, occurs in 50-80% of postpartum parents, peaks day 3-5 postpartum, resolves spontaneously by week 2. Symptoms milder (tearfulness, irritability, mood lability) without functional impairment. If symptoms persist beyond two weeks or worsen, evaluation for PPD is warranted.

vs. Postpartum psychosis

Rare (1-2 per 1,000 births) but psychiatric emergency. Onset typically within 2 weeks postpartum. Features: mood instability, psychotic symptoms (delusions, hallucinations), confusion, severe insomnia, command auditory hallucinations regarding baby. Requires immediate psychiatric hospitalization. Often associated with underlying bipolar disorder.

vs. Postpartum anxiety disorders

Generalized anxiety, panic disorder, and postpartum OCD (often with intrusive thoughts about baby harm) occur peripartum and may be missed because depression screening doesn't capture them. EPDS includes some anxiety items but is not a comprehensive anxiety screen. Suspect when anxiety features predominate over depressed mood.

vs. Pre-existing depression with peripartum exacerbation

Patients with established depression history often experience exacerbation during pregnancy or postpartum. The diagnostic criteria are the same; the clinical implications include earlier and more aggressive treatment because untreated depression in pregnancy has documented adverse outcomes for both parent and child.

First-line treatments

Sertraline (and other lactation-compatible SSRIs)

Sertraline is generally considered the first-line SSRI in lactation because of low transfer to breastmilk and minimal infant exposure in published cohorts. Paroxetine and citalopram are reasonable alternatives. Avoid fluoxetine in lactation when alternatives exist (longer half-life, more infant exposure). Standard antidepressant titration; onset 4-8 weeks; continue 6-12 months minimum after response.

Brexanolone (Zulresso)

FDA-approved for PPD in 2019. IV neurosteroid (synthetic allopregnanolone), 60-hour continuous infusion in REMS-monitored setting. Effect within hours; sustained over weeks. High cost; access limited by infusion logistics. Reserved for moderate-to-severe PPD with rapid-onset need. The Meltzer-Brody 2018 Lancet trial established efficacy.

Zuranolone (Zurzuvae)

FDA-approved for PPD in 2023. Oral neurosteroid, 14-day treatment course (one bedtime dose nightly for 14 days). More accessible than brexanolone (no infusion). Effect emerges within first week; sustained over weeks following the 14-day course. Cost considerations and insurance variability. Same GABA-A positive allosteric modulator mechanism as brexanolone.

Cognitive-behavioral therapy (CBT)

Evidence-based psychotherapy for PPD with effect sizes comparable to medication monotherapy in many trials. Accessible via telehealth (an important consideration for parents of newborns). Combination with medication outperforms either alone in moderate-to-severe PPD. Interpersonal therapy (IPT) is an alternative with comparable evidence specific to perinatal populations.

Social support and structured help

Sleep deprivation, social isolation, and overwhelming caregiving demands are not just consequences of PPD but contributors. Concrete interventions — partner overnight care to allow consolidated sleep blocks, lactation support to reduce feeding stress, postpartum doulas, family help — are part of treatment, not separate from it. Practitioners should specifically inquire about and help arrange these supports.

Light therapy

Bright light therapy (10,000 lux, 30 min morning) has evidence in peripartum depression and is appealing because of no breastfeeding concerns and no medication exposure. Effect sizes modest as monotherapy; useful as adjunct or for mild-to-moderate PPD with seasonal features.

Group support and peer programs

Programs like Postpartum Support International, group CBT, and structured peer support reduce isolation and provide normalization of common postpartum experiences. Particularly valuable for parents who do not have available social support in their immediate community.

When standard treatments fail

For PPD that does not respond to first-line SSRI plus CBT: optimize current SSRI (dose increase, duration extension) → switch to second SSRI or SNRI → consider brexanolone or zuranolone if not already used (rapid-onset options especially relevant in moderate-to-severe PPD) → add atypical antipsychotic augmentation if breastfeeding considerations allow → consider rTMS (no medication exposure) → consider ECT in severe PPD particularly with suicidality, psychotic features, or catatonic features. For breastfeeding patients, the menu of options is narrower because of lactation compatibility considerations — but most first-line and second-line options have manageable lactation profiles, and the LactMed database (NIH) is the standard resource for drug-specific data.

Where ketamine fits

Ketamine in PPD specifically has a preliminary evidence base. Single-dose perioperative ketamine (administered at cesarean delivery) has been studied for PPD prevention with mixed results across trials. Treatment of established PPD with ketamine is largely investigational; published clinical use is case-series-level. Key considerations: breastfeeding compatibility is uncertain — ketamine and metabolites pass into breastmilk; published guidance suggests pumping and discarding milk for at least 24 hours after a session. This significantly limits practical use in actively breastfeeding patients. For PPD patients who have failed adequate trials of SSRIs, CBT, and the FDA-approved PPD-specific options (brexanolone or zuranolone), ketamine becomes a reasonable consideration, particularly in patients no longer breastfeeding. The Deligiannidis 2025 Br J Psychiatry review provides current framing for neurosteroid treatments in PPD and broader implications.

Where this fits with Tovani

Tovani treats postpartum depression with caution and appropriate context. Patients who are actively breastfeeding are typically advised to first try FDA-approved PPD-specific options (zuranolone is now available outpatient) and standard SSRI therapy before considering ketamine, because the breastfeeding lactation profile of ketamine is less well-characterized. For patients no longer breastfeeding (or who have weaned), or for whom the standard options have failed, ketamine becomes a reasonable consideration. The screening explicitly addresses breastfeeding status, prior treatment trials, and severity. Coordination with the patient's OB/GYN or perinatal psychiatry provider is the norm.

Check eligibility The science behind ketamine

Frequently asked

How is postpartum depression different from baby blues?

Baby blues is transient (resolves spontaneously within 2 weeks), occurs in most postpartum parents, and does not produce functional impairment. PPD is a major depressive episode that persists beyond 2 weeks, often worsens rather than resolves, and impairs caregiving capacity. The Edinburgh Postnatal Depression Scale (EPDS) helps differentiate — score ≥10 warrants assessment; ≥13 strongly suggests PPD.

Are antidepressants safe while breastfeeding?

Generally yes for the most commonly used options. Sertraline is the first-line SSRI in lactation because of low transfer to breastmilk and minimal documented infant exposure. Paroxetine and citalopram are reasonable alternatives. Fluoxetine has more infant exposure (longer half-life) and is typically avoided when alternatives exist. The NIH LactMed database is the standard resource for drug-specific lactation data.

Should I try brexanolone or zuranolone before considering ketamine?

Yes, in most cases. Brexanolone (IV, 60-hour infusion) and zuranolone (oral, 14-day course) are FDA-approved specifically for PPD and have been studied in PPD populations. Ketamine is off-label and has a smaller PPD-specific evidence base. The clinical sequence typically prioritizes SSRIs and FDA-approved PPD options first, with ketamine reserved for treatment-resistant cases or patients no longer breastfeeding.

Can I take ketamine while breastfeeding?

Uncertain. Ketamine and metabolites do pass into breastmilk; published guidance suggests pumping and discarding milk for at least 24 hours after a session. Many clinicians recommend deferring ketamine treatment until after weaning if possible, especially when other effective options (zuranolone, SSRIs, CBT) are available. Tovani screens for breastfeeding status and discusses these considerations in eligibility.

What if I'm having intrusive thoughts about my baby?

Mention this to your clinician. Intrusive thoughts about harm coming to your baby (or rarely, fleeting thoughts of causing harm) are common in PPD and even more characteristic of postpartum OCD — they do not predict you will act on them. They are distressing and treatable. Symptoms that include true command hallucinations, conviction the thoughts are correct, or psychotic features require immediate psychiatric evaluation for possible postpartum psychosis, which is a different entity requiring urgent care.

References

MeltzerBrody S et al. 2018, Lancet — Phase 3 RCTs of brexanolone in postpartum depression — establishes efficacy of the GABA-A positive allosteric modulator mechanism for PPD specifically, supporting subsequent FDA approval. (PMID 30177236)
Deligiannidis KM, Meltzer-Brody S. 2025, British Journal of Psychiatry — Review of neurosteroid treatments for postpartum depression and beyond — current evidence base for brexanolone and zuranolone, mechanism, and positioning relative to standard antidepressants. (PMID 40470759)
Cipriani A et al. 2018, Lancet — Network meta-analysis of antidepressants in adult depression — informs SSRI sequencing decisions in PPD, including lactation compatibility considerations. (PMID 29477251)

Last reviewed by Dr. Ben Soffer, DO on May 27, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.